|
|
News Breaks | | | | December 6, 2012 | | 16:02 EDT |  | BIOD | Biodel: FDA grants orphan drug designation for Glucagon
Biodel announced that the FDA has granted orphan drug designation for Biodel's 'glucagon' for the prevention of hypoglycemia in the congenital hyperinsulinism population. The FDA grants orphan designation to promote development of therapies to treat rare diseases. Once this designation is granted, the sponsor may be eligible for a range of incentives including FDA grant funding for clinical trial costs, tax credits related to development expenses, waiver of FDA user fees, and a seven-year period of marketing exclusivity in the U.S. following FDA approval. | |
|
News For BIOD From The Last 14 Days Check below for free stories on BIOD the last two weeks. |
|
|
| May 14, 2013 | | 06:23 EDT |  | BIOD | Biodel files $75M mixed securities shelf
| |
|
|
|
|
|
|
